Last updated: November 11, 2026
Thyrotropin alfa, marketed as Thyrogen by Sanofi, is a recombinant human thyroid-stimulating hormone used primarily in differentiated thyroid cancer management. Its commercial profile is mature rather than growth-driven: U.S. regulatory exclusivity expired years ago, no approved biosimilar or generic substitute is publicly listed, and Sanofi does not separately disclose Thyrogen revenue in recent annual reports. Demand is supported by thyroid cancer surveillance, avoidance of temporary hypothyroidism, and established use in radioactive iodine preparation and follow-up testing. [1][2][3]
What is thyrotropin alfa and how is it used?
Thyrotropin alfa is recombinant human TSH, a heterodimeric glycoprotein produced in genetically engineered Chinese hamster ovary cells. It reproduces the activity of endogenous TSH without requiring patients to stop thyroid hormone replacement for several weeks.
The main clinical uses are:
| Use |
Commercial relevance |
| Radioactive iodine remnant ablation preparation |
Supports use after thyroidectomy in selected differentiated thyroid cancer patients |
| Diagnostic radioactive iodine imaging |
Enables testing while patients remain on thyroid hormone replacement |
| Serum thyroglobulin stimulation testing |
Improves surveillance for residual or recurrent thyroid cancer |
| Avoidance of hormone withdrawal |
Reduces hypothyroid symptoms, work disruption, and logistical burden |
The U.S. label covers use as an adjunct for radioactive iodine imaging or treatment in patients who have undergone thyroidectomy for well-differentiated thyroid cancer and as an adjunct to serum thyroglobulin testing. [1]
Thyrogen is administered intramuscularly, usually as two injections on consecutive days. A radioactive iodine procedure or thyroglobulin test generally follows the second dose. The short treatment course supports premium pricing compared with standard thyroid hormone withdrawal, although reimbursement and institutional protocols determine actual utilization.
When did Thyrogen receive FDA approval and lose exclusivity?
The FDA approved Thyrogen in 1998. The product was originally developed by Genzyme, which Sanofi acquired in 2011. [1][4]
| Milestone |
Date |
| FDA approval of Thyrogen |
1998 |
| Genzyme acquisition by Sanofi |
2011 |
| Original U.S. biologic exclusivity period |
Expired |
| Current U.S. marketing status |
Approved, marketed product |
| Approved U.S. biosimilars |
None publicly listed |
| Orange Book applicability |
Not applicable as a biologic licensed under a BLA |
The Biologics Price Competition and Innovation Act created a 12-year reference-product exclusivity period for new biologics, but Thyrogen predates that framework. Its statutory exclusivity therefore expired long ago. Patent expiry, regulatory exclusivity, and commercial availability are separate issues. The absence of current exclusivity does not automatically produce competition if development economics, manufacturing complexity, clinical adoption, and market size discourage entrants.
What is the patent and regulatory status of thyrotropin alfa?
Thyrotropin alfa is regulated under a biologics license application rather than a conventional new drug application. The relevant FDA application is BLA 103012. [1]
Is Thyrogen listed in the Orange Book?
No conventional Orange Book patent listing should be expected for Thyrogen because the Orange Book primarily covers approved drug products submitted under NDAs and abbreviated new drug applications. Biologics licensed under BLAs are tracked through FDA biologics systems and the Purple Book framework rather than through the standard Orange Book patent-certification process. [5][6]
This distinction affects generic-entry analysis:
- An ANDA-based Paragraph IV pathway is not the standard route for Thyrogen.
- A follow-on biological product would generally require a biosimilar application under section 351(k) of the Public Health Service Act.
- No approved U.S. biosimilar to thyrotropin alfa is publicly identified in the FDA Purple Book as of the latest available public records reviewed. [6]
- Any remaining patent protection would need to be assessed separately from FDA exclusivity and Orange Book listing status.
What patents protect Thyrogen?
The original product was protected by a combination of biologic manufacturing know-how, recombinant protein production technology, formulation work, regulatory exclusivity, and potentially product-specific patent rights. Publicly available FDA records do not provide a current, definitive Orange Book-style patent list for Thyrogen.
The most material protection today is likely operational rather than statutory:
- Experience manufacturing a correctly folded, glycosylated recombinant TSH.
- Product-specific analytical methods and release specifications.
- Process consistency for a complex glycoprotein.
- Clinical and regulatory experience in thyroid cancer workflows.
- Physician familiarity and institutional protocols.
These barriers can slow entry but do not create a legal monopoly comparable to an unexpired composition-of-matter patent.
How strong is the thyrotropin alfa patent estate?
The patent estate appears commercially moderate but legally mature.
| Protection category |
Current assessment |
| Regulatory exclusivity |
Expired |
| Orange Book protection |
Not the applicable framework |
| Current composition-of-matter exclusivity |
No clearly active foundational exclusivity identified in public FDA materials |
| Manufacturing know-how |
Potentially meaningful |
| Formulation protection |
Possible historical relevance; no current public exclusivity established here |
| Method-of-use protection |
Historical patents may have covered diagnostic or treatment uses, but the core clinical uses are mature |
| Biosimilar litigation risk |
Low in the near term because no identified U.S. biosimilar entrant is active |
| Entry barrier |
Manufacturing and market economics are more important than regulatory exclusivity |
The estate is therefore stronger as a commercial franchise than as a conventional patent-protected product. Sanofi's position depends on supply reliability, physician acceptance, reimbursement, and the cost of developing and validating a competing recombinant glycoprotein.
What formulations and manufacturing processes are protected?
Thyrogen is supplied as a lyophilized powder for reconstitution. The formulation contains recombinant thyrotropin alfa with excipients that support stability and administration after reconstitution. [1]
Potentially protectable technical areas include:
- Cell-line construction and expression systems.
- Protein folding and glycosylation control.
- Purification and impurity removal.
- Lyophilization and reconstitution stability.
- Potency assays and glycoprotein characterization.
- Container-closure and cold-chain handling.
- Batch consistency and comparability protocols.
These elements may be protected by patents, trade secrets, or regulatory know-how. Process patents can expire while trade-secret advantages remain. A competitor would still need to demonstrate identity, purity, potency, safety, and clinical similarity for a biosimilar or other follow-on biologic.
Manufacturing is more complex than producing a conventional small-molecule thyroid medicine. The active ingredient is a recombinant glycoprotein with structural attributes that can affect receptor activity, pharmacokinetics, immunogenicity, and assay performance. That complexity limits the commercial attractiveness of a low-price entrant in a specialized market.
What is the current market for thyrotropin alfa?
Thyrogen operates in a narrow specialty market linked to differentiated thyroid cancer. The product does not compete across the broad thyroid hormone replacement market, which is dominated by inexpensive levothyroxine.
Primary demand drivers
Demand is supported by:
- Increasing numbers of thyroid cancer survivors requiring long-term surveillance.
- Greater use of risk-stratified monitoring.
- Patient preference to avoid thyroid hormone withdrawal.
- Reduced productivity loss and hypothyroid symptoms.
- Endocrinology and nuclear medicine protocols that incorporate recombinant TSH.
- Continued use of radioactive iodine in selected patients.
The American Cancer Society estimates that thyroid cancer is among the more commonly diagnosed cancers in the United States, although incidence patterns and diagnostic intensity have changed over time. The large survivor population creates a recurring surveillance market rather than a one-time treatment market. [7]
Demand constraints
Use is limited by:
- High acquisition cost relative to thyroid hormone withdrawal.
- Reimbursement restrictions and prior authorization.
- Clinical debate over radioactive iodine use in lower-risk disease.
- Variation in institutional treatment protocols.
- Availability of thyroid hormone withdrawal as a lower-cost alternative.
- Reduced radioactive iodine use in selected low-risk patients.
The product is therefore sensitive to both cancer-management guidelines and payer policy. Growth in thyroid cancer survivorship does not translate directly into equivalent unit growth.
What is the financial trajectory of Thyrogen?
Sanofi does not provide a consistently separate Thyrogen revenue line in its consolidated public reporting. The product is reported within broader business categories, which prevents a reliable standalone revenue series from public annual reports. [2][3]
The financial trajectory can be characterized by lifecycle stage rather than exact revenue:
| Period |
Financial profile |
| 1998-2000s |
Specialty biologic launch and adoption in thyroid cancer care |
| 2000s-early 2010s |
Expansion through broader physician familiarity and Genzyme commercialization |
| Post-2011 |
Integration into Sanofi's specialty-care portfolio |
| Mature period |
Stable or slow-growth demand, supported by recurring surveillance |
| Current period |
Margin and cash-flow contribution likely depend on pricing, manufacturing efficiency, and limited direct competition |
The product is unlikely to be a major driver of Sanofi's consolidated financial performance. Sanofi's current growth reporting is concentrated in larger franchises such as Dupixent, vaccines, immunology, rare disease, and other specialty medicines. Thyrogen is a mature, niche asset whose value is more likely to come from durable cash generation than from rapid sales expansion. [2][3]
Revenue exposure and valuation implications
Because standalone revenue is not disclosed, investors and licensing parties should not assign a precise revenue trajectory based on Sanofi group results. A practical commercial assessment is:
- Revenue base: specialty and relatively narrow.
- Growth profile: low to moderate, dependent on diagnosis and surveillance volume.
- Pricing: potentially resilient because the product avoids hormone withdrawal, but payer-sensitive.
- Gross-margin profile: potentially favorable after recovery of development costs, subject to biologic manufacturing expenses.
- Competition: limited direct competition but meaningful substitution by thyroid hormone withdrawal.
- Downside risk: payer restrictions, lower radioactive iodine use, supply disruption, or biosimilar entry.
- Upside risk: expanded use in surveillance, improved reimbursement, or broader adoption in selected ablation protocols.
Which companies are challenging Thyrogen?
No major approved U.S. biosimilar competitor is publicly listed for thyrotropin alfa. There is also no established branded recombinant TSH competitor with comparable U.S. market presence.
The principal competitive alternatives are non-company substitutes:
| Alternative |
Competitive effect |
| Thyroid hormone withdrawal |
Lower-cost clinical substitute; requires hypothyroid period |
| Endogenous TSH stimulation after withdrawal |
Established and widely available |
| Alternative surveillance strategies |
May reduce use in lower-risk patients |
| Future biosimilar thyrotropin alfa |
Could reduce price if development becomes economically viable |
A biosimilar entrant would face a small addressable market, complex analytical requirements, clinical comparability costs, and the need to secure reimbursement. Those factors reduce the probability of near-term entry even though legal exclusivity has expired.
What is the Paragraph IV and litigation risk?
Paragraph IV litigation is not the normal pathway for a biologic such as thyrotropin alfa. A conventional ANDA applicant would not typically challenge Thyrogen through the small-molecule Hatch-Waxman process because Thyrogen is licensed under a BLA.
A future biosimilar could create patent disputes through the BPCIA patent-exchange process, often called the "patent dance," rather than through a standard Paragraph IV certification. Potential disputes could address:
- Composition and sequence claims.
- Cell-line and expression technology.
- Purification and glycosylation.
- Formulation and stability.
- Manufacturing methods.
- Method-of-use claims.
No material, publicly established active U.S. biosimilar litigation against Thyrogen is identified in the cited FDA and company materials. Sanofi's main risk is not current litigation. It is the possibility that a technically capable entrant concludes the market is large enough to justify development.
What FDA regulatory status does Thyrogen have?
Thyrogen remains an FDA-approved biologic under BLA 103012. The approved product is supplied for intramuscular use and is indicated as an adjunct in differentiated thyroid cancer imaging, treatment preparation, and thyroglobulin testing. [1]
The FDA status supports continued sales, but approval does not guarantee reimbursement. Coverage decisions remain dependent on indication, payer policy, patient risk, and institutional protocols.
How does Thyrogen compare with thyroid hormone withdrawal?
| Factor |
Thyrogen |
Thyroid hormone withdrawal |
| Patient thyroid hormone status |
Maintained |
Temporarily stopped |
| Hypothyroid symptoms |
Usually avoided |
Common during withdrawal |
| Drug cost |
High |
Low |
| Administration |
Two injections |
No injection, but prolonged preparation |
| Scheduling |
Rapid, protocol-based |
Longer preparation period |
| Reimbursement sensitivity |
High |
Lower |
| Manufacturing complexity |
Recombinant biologic |
Generic hormone withdrawal |
| Commercial threat |
Direct product alternative |
Main substitution risk |
Thyrogen's value proposition is convenience and preservation of quality of life, not lower treatment cost. Its commercial durability depends on whether payers and physicians value those benefits enough to accept the price premium.
What generic launch scenarios exist for thyrotropin alfa?
Three scenarios are commercially relevant:
- No near-term follow-on entry. Sanofi retains the market because the addressable population is specialized and development economics are unattractive.
- A biosimilar launches with limited price erosion. The entrant targets large academic centers and integrated health systems while Sanofi retains share through clinical familiarity and supply reliability.
- Multiple entrants create meaningful price pressure. This would require a larger-than-expected market, favorable regulatory precedent, and a manufacturer with recombinant glycoprotein capabilities.
The most probable near-term scenario is continued branded dominance with gradual substitution pressure from clinical alternatives rather than an immediate biosimilar price collapse.
What geographic markets matter?
The United States is likely the most commercially important market because of its large thyroid cancer treatment infrastructure, specialty reimbursement system, and established use of recombinant TSH. Thyrogen has also been marketed internationally, subject to country-specific approvals and reimbursement. [1][4]
Geographic performance depends on:
- National reimbursement decisions.
- Radioactive iodine treatment practices.
- Availability of endocrinology and nuclear medicine services.
- Local pricing controls.
- Hospital procurement.
- Regulatory requirements for biologics.
In price-regulated markets, the product may have lower per-unit revenue but still retain use where avoiding thyroid hormone withdrawal is clinically valued.
Key Takeaways
- Thyrotropin alfa is a mature recombinant biologic marketed as Thyrogen by Sanofi.
- FDA approval dates to 1998, and original regulatory exclusivity has expired.
- Thyrogen is regulated under BLA 103012, not through the standard Orange Book pathway.
- No approved U.S. biosimilar is publicly identified in the FDA Purple Book.
- Sanofi does not separately disclose Thyrogen revenue, preventing a defensible standalone revenue forecast from public filings.
- The market is supported by differentiated thyroid cancer surveillance and avoidance of hypothyroidism.
- The main current substitute is thyroid hormone withdrawal, not a competing branded biologic.
- Manufacturing complexity and limited market size are more important barriers than active patent exclusivity.
- Near-term commercial risk is driven by reimbursement, radioactive iodine utilization, and potential biosimilar economics.
- The product is best viewed as a stable specialty cash-generating asset rather than a high-growth pharmaceutical franchise.
FAQs about thyrotropin alfa market access and competition
Is thyrotropin alfa a biologic or a small-molecule drug?
Thyrotropin alfa is a recombinant biologic, specifically a recombinant human glycoprotein hormone manufactured in Chinese hamster ovary cells.
Does Thyrogen have a biosimilar competitor?
No approved U.S. biosimilar to thyrotropin alfa is publicly listed in the FDA Purple Book based on the cited regulatory records.
Can a generic company file an ANDA for Thyrogen?
The standard ANDA route is not the expected pathway because Thyrogen is licensed under a BLA. A follow-on developer would generally pursue a biosimilar or other biologics pathway.
What is the largest commercial threat to Thyrogen?
The largest current threat is substitution by thyroid hormone withdrawal, which is less expensive but creates a period of hypothyroidism and requires longer preparation.
Does Sanofi disclose Thyrogen sales separately?
Sanofi's public financial reporting does not consistently disclose Thyrogen as a standalone revenue line, so product-specific sales and growth rates cannot be calculated reliably from consolidated filings.
Sources:
- U.S. Food and Drug Administration. (n.d.). Thyrogen (thyrotropin alfa) prescribing information and biologics license application records.
- Sanofi. (2024). 2023 Universal Registration Document and annual financial report.
- Sanofi. (2023). 2022 Universal Registration Document and annual financial report.
- Sanofi. (2011). Sanofi completes acquisition of Genzyme.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
- American Cancer Society. (2024). Thyroid cancer statistics and treatment information.
